世界中医药2017，Vol.12Issue(7)：1594-1596,1600,4.DOI:10.3969/j.issn.1673-7202.2017.07.029
血脂康对介入术后冠心病合并高血脂患者预后的影响
Effect of Xuezhikang on the Prognosis of Patients with Coronary Heart Disease Complicated with Hyperlipidemia after Interventional Therapy
摘要
Abstract
Objective:To observe the effect of Xuezhikang on cardiac function in patients with coronary disease after percutaneous coronary intervention,and to observe the effect of Xuezhikang on blood lipid and plasma FIB level.Methods:Collect 80 patients with coronary disease after percutaneous coronary intervention in our hospital from 2015 to 2016 were randomly selected.The patients were divided into control group and observation group,40 cases in each group.Two groups of patients were treated with basic treatment,the control group was given atorvastatin calcium treatment,the treatment group in the control group on the basis of taking Xuezhikang treatment,were treated for 4 weeks.The levels of blood lipid,plasma Fib,PAI-1 and t-PA were detected before and after treatment,and the cardiac function was evaluated before and after treatment and 3 months after the treatment.Results:After treatment,two patients;1) TG,TCHO,HDL-C and LDL-C were lower than those before treatment(P ＜ 0.05),the degree of improvement and the index of the treatment group was significantly better than the control group(P ＜ 0.05);2)two groups of plasma Fib and PAI-1 after treatment were decreased,t-PA value increased (P ＜ 0.05),and the treatment group was significantly better than the control group(P ＜ 0.05);3)the two groups after treatment in patients with heart function were improved,the treatment group than the control group(P ＜ 0.05),and 3 months after the indicators were better than the control group(P ＜ 0.05).Conclusion:Xuezhikang can reduce blood lipid level of hyperlipidemia patients with coronary disease,improve the blood coagulation,and can significantly improve the prognosis of cardiac function level.关键词
血脂康/冠心病/高脂血症/心功能/预后/血浆FIBKey words
Xuezhikang/Coronary disease/Hyperlipidemia/Cardiac function/Prognosis/FIB分类
医药卫生引用本文复制引用
张建国,朱正炎,马军力,王礼..血脂康对介入术后冠心病合并高血脂患者预后的影响[J].世界中医药,2017,12(7):1594-1596,1600,4.基金项目
北京市教育局科研项目(2013WJ009) （2013WJ009）
